Vaxcyte Inc’s filing revealed that its SVP, GEN COUNSEL & CORP SEC Eydelman Mikhail unloaded Company’s shares for reported $0.35 million on Mar 05 ’25. In the deal valued at $70.74 per share,5,000 shares were sold. As a result of this transaction, Eydelman Mikhail now holds 41,620 shares worth roughly $1.43 million.
Then, Eydelman Mikhail bought 5,000 shares, generating $344,350 in total proceeds.
Before that, Wassil Jim sold 8,000 shares. Vaxcyte Inc shares valued at $586,165 were divested by the CHIEF OPERATING OFFICER at a price of $73.27 per share. As a result of the transaction, Wassil Jim now holds 154,931 shares, worth roughly $5.32 million.
Cantor Fitzgerald initiated its Vaxcyte Inc [PCVX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Mizuho began covering PCVX with “Buy” recommendation on December 07, 2023. TD Cowen started covering the stock on April 18, 2023. It rated PCVX as “an Outperform”.
Price Performance Review of PCVX
On Monday, Vaxcyte Inc [NASDAQ:PCVX] saw its stock fall -0.67% to $34.33. Over the last five days, the stock has lost -7.72%. Vaxcyte Inc shares have fallen nearly -58.06% since the year began. Nevertheless, the stocks have fallen -53.56% over the past one year. While a 52-week high of $121.06 was reached on 01/28/25, a 52-week low of $27.66 was recorded on 04/10/25.
Levels Of Support And Resistance For PCVX Stock
The 24-hour chart illustrates a support level at 33.40, which if violated will result in even more drops to 32.47. On the upside, there is a resistance level at 35.10. A further resistance level may holdings at 35.87.
The most recent change occurred on January 03, 2023 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $58.
